In late 2019, Congress enacted the “CREATES Act”, which established a private right of action in which generic or biosimilar manufacturers may sue an innovator for an injunction and monetary award for not selling samples of...more
9/6/2022
/ Anticompetitive Behavior ,
Biosimilars ,
Continuing Legal Education ,
CREATE Act ,
Generic Drugs ,
Injunctions ,
Innovator Liability ,
Life Sciences ,
Pharmaceutical Industry ,
Private Right of Action ,
Webinars